The first people's therapeutic transgenic cow of antibody of our country was born

The first people's therapeutic transgenic cow of antibody of our country was born
The first people's therapeutic transgenic cow of antibody of our country was born
According to the report of Beijing (Xinhua) the 11th August ' Reporter Li JingHua) Research and development group led by China Agricultural University academician Li Ning, help general continuous heavy rain biotechnology Co., Ltd. and Beijing department and moisten Wade biotechnology Co., Ltd. and work in concert with Beijing, in the intersection of Beijing and transgenic the intersection of animal and proving ground, born one hair transferring the intersection of people and " the the intersection of CD20 and the intersection of antibody and gene " to healthy smoothly a few days ago Transgenic cow. This transgenic cow's birth weight is 38 kilograms, health status is good. People CD20 monoclonal antibody are specific medicines to treat malignant tumour such as B lymphocyte tumour at present. Train the person CD20 antibody that the way produced through mammalian cells at present, it is the first antitumor monoclonal antibody medicine that the American food medicines administration bureau sanctioned, the global sales amount can reach more than 3 billion dollars every year. But this kind of people CD20 antibody medicine production cost is high, cost an arm and a leg, a course of treatment (inject for 4 times) Need to cost 16,000 dollars, this is an enormous burden to most patients. Academician Li Ning researches and develops the project of the group just through transgenic technology, gets the transgenic cow's mammary gland bioreactor, make the milk of the transgenic cow contain people CD20 monoclonal antibody. This monoclonal antibody is prepared into specific drug of cancer, can reduce production cost to original 1/10 through the purification, the expected new route to open up production of a monoclonal antibody, thus bring good news for cancer patients such as lymphocyte tumour of global B,etc.. Animal's mammary gland bioreactor is new stage the most of pharmacy of genetic engineering, it is a kind of brand-new production mode, have superiority which past pharmacy technology can't compare: First, the medicine albumen produced is wide in variety, the output is high, have steady biological activity in nature; Second, production cycle is short, the cost is low; Third, safe environmental protection, the apparatus is simple, it is low to consume energy, there is no environmental pollution. On the basis of the enormous commercial promise of animal's mammary gland bioreactor, the governments and enterprises of various countries have strengthened the research and development investment to animal's mammary gland bioreactor one after another, try hard to occupy a tiny space in the international competition of animal's mammary gland bioreactor industry. Success of this transgenic cow is got, indicates the animal bioreactor of our country has researched and developed and entered higher developing stage, have realized and moved ahead simultaneously with the American-European developed country in utilizing the transgenic animal to produce antibody medicines, have laid the solid foundation for low cost of the antibody medicine, large-scale production.


|